Throughout the last decade, more and more companies have popped up that are focused on discovering and developing psychedelic compounds to revolutionize the treatment of mental illness. A number of these companies, including Atai Life Sciences ATAI and Compass Pathways CMPS are already publicly traded.
But today we will take a closer look at some of the psychedelic-focused companies that are private, specifically those that have raised the most money. The information below was compiled from Psilocybin Alpha.
Beckley Psytech
Beckley Psytech is a private company utilizing multiple different psychedelics compounds to address a myriad of mental health issues, according to Psilocybin Alpha.
The founders of Beckley Psytech bring valuable experience in the space from running the Beckley Foundation, a non-profit focused on furthering the psychedelic space founded in 1998.
“We collaborate with leading scientific and political institutions worldwide to design and develop ground-breaking research and global policy initiatives,” according to the foundation’s website.
In August 2021, Beckley announced it raised around $80 million in a Series B financing round.
Visit Beckley Psytech’s website to learn more.
Delix Therapeutics
Delix Therapeutics is a company specializing in “psychoplastogens,” novel neuroplasticity-promoting therapeutics. Delix hopes these psychoplastogens will have strong efficacy while providing a safe alternative to other drugs in the space.
Delix's compounds are small molecules that can effectively target the desired areas of the brain.
In September 2021, Delix announced it closed a $70 million Series A financing round.
Visit Delix’s website to learn more.
Gilgamesh Pharmaceutical
Gilgamesh is a private, pre-clinical biotech company focused on developing new chemical entities (NCEs) in the psychedelic space. Gilgamesh has an AI-powered drug development program, ENKIDU, named after the character in the “Epic of Gilgamesh” ancient tale
So far, Gilgamesh has four drugs in its pipeline, with three focused on alleviating the effects of depression, and the fourth in helping patients beat opioid addiction.
In May 2021, Gilgamesh announced the closing of its Series A financing round, raising $27 million.
Visit Gilgamesh Pharmaceutical’s website to learn more.
Editor's note: A previous version of this story did not properly cite Psilocybin Alpha.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!